An open-label, 4-year extension study of ixekizumab yields promising results.
mdedge.com
GENEVA – Clear nails in half of ixekizumab users by week 24.
mdedge.com
KAUAI, HAWAII – “If this holds up in phase 3, it’s going to be a new world for our patients and for us, ” said Craig L. Leonardi, MD.
mdedge.com